Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P.
Perilongo G, et al. Among authors: brugieres l.
N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.
N Engl J Med. 2009.
PMID: 19846851
Free article.
Clinical Trial.